AbbVie’s $10.9 Billion Bid Spurs Hold Rating and 46.8% Stock Surge
APGE•AbbVie’s $10.9 billion cash offer for Apogee Therapeutics prompted a Craig-Hallum downgrade from Buy to Hold due to limited upside. Shares jumped 46.8% to a 52-week high as Halper Sadeh LLC launched a fairness investigation into the sale.
1. Acquisition Details
AbbVie will acquire Apogee Therapeutics in an all-cash transaction valued at $10.9 billion. The purchase aims to strengthen AbbVie’s immunology drug lineup with Apogee’s clinical-stage inflammatory treatments.
2. Analyst Downgrade Rationale
Craig-Hallum downgraded Apogee from Buy to Hold, citing that the cash offer price leaves minimal upside for shareholders. The firm expects the shares to track the broader market rather than deliver significant gains post-deal.
3. Share Price Reaction
On the downgrade and acquisition announcement, Apogee’s shares jumped 46.8% to reach a 52-week high. The surge reflects investor enthusiasm for the premium bid despite limited future appreciation beyond the offer price.
4. Investigation by Halper Sadeh LLC
Investor rights law firm Halper Sadeh LLC initiated a fairness review of the sale process. The probe examines whether Apogee’s board secured the best possible price and fully disclosed key information to shareholders.
